tumors sequenced to help guide treatment decisions. Newer commercially available tumor sequencing tests can provide information on hundreds of genes. But controversy remains about who should pay for these tests.
On March 16, the Centers for Medicare and Medicaid Services (CMS), the federal agency that oversees Medicare and Medicaid,
announced that Medicare would start paying for certain next-generation sequencing testing approved or cleared by the U.S. Food and Drug Administration (FDA) for patients with advanced cancer, effective immediately.
announced that Medicare would start paying for certain next-generation sequencing testing approved or cleared by the U.S. Food and Drug Administration (FDA) for patients with advanced cancer, effective immediately.
Next-generation sequencing is a relatively recent addition to the set of tools doctors can use to run diagnostics on their patients’ cancer. There are still plenty of questions to be answered about the technology itself and the recent coverage decision.
Cancer Today spoke with experts to find out what patients need to know about this form of testing and how it’s paid for.
Cancer Today spoke with experts to find out what patients need to know about this form of testing and how it’s paid for.
No comments:
Post a Comment